Connor Clark & Lunn Investment Management Ltd. Reduces Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Connor Clark & Lunn Investment Management Ltd. trimmed its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 201,569 shares of the specialty pharmaceutical company's stock after selling 13,295 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.37% of Supernus Pharmaceuticals worth $7,289,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Smartleaf Asset Management LLC raised its stake in shares of Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth about $72,000. Venturi Wealth Management LLC purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth about $92,000. KBC Group NV grew its position in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock worth $97,000 after buying an additional 929 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth about $211,000.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is currently owned by corporate insiders.

Remove Ads

Supernus Pharmaceuticals Trading Down 0.8 %

Shares of SUPN traded down $0.25 during midday trading on Wednesday, reaching $32.03. The stock had a trading volume of 517,277 shares, compared to its average volume of 557,342. The company's 50-day moving average is $36.02 and its 200 day moving average is $35.13. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of 29.93 and a beta of 0.83.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on SUPN shares. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.